Enoxaparin - VTE treatment in pregnancy

You are here : Home > Formulary Search > Enoxaparin - VTE treatment in pregnancy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Off-label use. Prescribe by brand: RSCH / SASH / ASPH = Inhixa brand

Documentation

Guidelines (Local)

NWS Enoxaparin Brand switch primary care comms Nov 2024

PAD Profile

ChemicalSubstance :

Enoxaparin

Indication :

VTE treatment in pregnancy

Group Name :

Keywords :

LMWH, low molecular weight heparins, venous thromboembolism

Brand Names Include :

Clexane, Inhixa, enoxaparin BECAT, Arovi

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Enoxaparin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat VTE treatment in pregnancy.

Committee Recommendations (2)

06 Nov 24 - NW Surrey Medicines Optimisation Group

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

22 Jan 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

Note; differences in the mechanisms for operation in needle guard between presentations of enoxaparin.